CBD Month: Empire Hemp Co. teaches the ABCs of CBD – The Daily News Online

January is National CBD month. The month is intended to celebrate and raise awareness of CBD or Cannabidiol, the non-addictive chemical in the Cannabis sativa plant, which is also known as cannabis or hemp. The plant does not have psychoactive effects, meaning it does not cause the “high” associated with THC (tetrahydrocannabinol).

“CBD comes in many forms, but not all CBD is created equally,” said Shelly Wolanske, COO of Empire Hemp Co., whose company’s products are all handcrafted in Batavia,

As an Amazon Associate I earn from qualifying purchases.

Sales Revenue in the Vaporizer Market to Register a Stellar CAGR … – Digital Journal

PRESS RELEASE

Published January 28, 2023

Vaporizer Market

A study by PMR concludes that, “Vaporizer Market: Global Opportunities, Challenges, Strategies and Forecasts 2025” has been added on Persistence Market Research.

The vaporizer market has grown significantly in recent years, reaching a market size of a few billion dollars. Vaping is done using a vaporizer. Inhaling and exhaling water vapour created by an electric device, such as a vaporizer or an e-cigarette, is known as vaping. With the use of vaporizers, users inhale and exhale gaseous e-liquid, which is the form of water vapour in the vaporizer.

Request for Free Sample [email protected]  https://www.persistencemarketresearch.com/samples/14026

Although the smoke from vaporizers is typically heavier, it dissipates into the air around it more rapidly, and it smells much better—typically like fruit, candy, or mint, depending on the flavouring that is being used. While vaping is a smoke-free alternative to regular tobacco cigarettes that may or may not include nicotine, it cannot be compared to smoking because there is no smoke produced.

As far as drivers of the vaporizer market are concerned, more than one third of the total population of the United States are cigarette smokers. Smoking related illnesses account for every one of five deaths in the United States. In addition, nearly 70% of the smokers report that they want to quit smoking to lead a healthier life and 42% of the smokers have tried to quit smoking unsuccessfully. Hence, it is obvious that there is a huge market for e-cigarettes and vaporizers in the United States alone, and the potential for other regions of world if included, then it would be a gigantic market.

Contact Sales for Further Assistance in Purchasing This [email protected] https://www.persistencemarketresearch.com/checkout/14026

Regional analysis includes: (Vaporizer Market)

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain)
  • Eastern Europe (Poland, Russia)
  • Asia Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

Request For Customization @  https://www.persistencemarketresearch.com/request-customization/14026

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Report Highlights:  (Vaporizer Market)

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

Read More Trending “PMR Exclusive Article”-https://www.openpr.com/news/1037569/vaporizer-market-higher-mortality-rates-by-2025.html 

About us:

The Consumer Goods team at Persistence Market Research helps clients from all over the globe with their unique business intelligence needs by offering expert analysis, actionable insights, and strategic recommendations. With a repertoire of over 1,000 reports and 1 million+ data points, the team has analyzed the consumer goods industry lucidly in 50+ countries for over a decade. We provide end-to-end research and consulting services; reach out to explore how we can help.

Contact Us

Persistence market research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]

This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on [email protected]

WRITTEN BY

Xherald

Xherald is passionate about offering extensive coverage of global business news. Dedicated to creating every participant’s notification, it reaches its own reader. Daily our experts offer fresh relevant information regarding what is actually occurring in Markets as well as Business. Our headlines are actually swiftly paced and extensive. Our distributor directory connects you with brand new products or services and its market situation from the most effective companies around the planet. Xherald is driven by its 500+ contributors coming from around the world. Xherald provides local as well as global market intelligence information coverage in sectors ranging from healthcare, IOT, chemicals and 17 more sectors. Our updates are quickly paced and detailed. The news we present is actually a mix of authentic content, community contributions and curated headlines announcements. All of the updates our company supplies must pass a strict criterion of genuineness, relevance and significance to our readers.

Massachusetts marijuana sales surpass $4 billion – CBS Boston


Cannabis overtakes cranberries as top crop in Massachusetts

Cannabis overtakes cranberries as top crop in Massachusetts 01:46

BOSTON – More than $4 billion worth of marijuana products have been sold in Massachusetts since the first pot shops opened in November 2018, the Cannabis Control Commission announced Friday.

„This industry is rapidly growing, it’s massive, it’s not going anywhere,” Cannabis Control Commissioner Ava Concepcion recently told WBZ-TV. „We’ve surpassed cranberries as being the cash crop of Massachusetts.” 

Voters legalized recreational cannabis use in 2016, and sales began about two years later. 

So far in 2023, there’s been over $85 million in marijuana retail sales, according to Cannabis Control Commission data.

Marijuana is subject to a 6.25% state sales tax and 10.75% state excise tax. Cities and towns can add an additional tax of up to 3%.

Marijuana Legalization Efforts Gain Traction Across the U.S. – Kiplinger’s Personal Finance

The Southeast is warming to the legalization of cannabis, and approval surrounding medical and recreational weed is gaining momentum. 

Alabama’s licensing process is underway, and efforts for weed legalization in Florida are building. South Carolina is making progress on its medical cannabis legalization program too.

Last week, Republican Senator Tom Davis introduced the South Carolina Compassionate Care Act (opens in new tab), with adjustments to avoid problems that derailed the reform previously. An earlier version of the bill cleared the South Carolina Senate but failed to pass the House floor due to issues related to language on taxes. If the bill passes this time, patients in South Carolina will gain access to cannabis through licensed dispensaries with a doctor’s recommendation. 

Subscribe to Kiplinger’s Personal Finance

Be a smarter, better informed investor.

Save up to 74%

Sign up for Kiplinger’s Free E-Newsletters

Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more – straight to your e-mail.

Profit and prosper with the best of expert advice – straight to your e-mail.

Weed legalization is already supported by most U.S. voters. And in November, a poll released by Winthrop University (opens in new tab) found that 78% of adults in South Carolina, including a majority of Republicans, would like to see medical cannabis reform. An additional 54% of voters were in favor of recreational weed legalization.

„The South Carolina Compassionate Care Act has been thoroughly vetted over eight years and incorporates numerous provisions to address concerns,” Director of State Policies Karen O’Keefe told Marijuana Moment (opens in new tab). „Sen. Davis’s 2023 bill reflects years’ of input and removes the tax and revenue allocation provisions that derailed last year’s bill in the House.”

We are especially keen on legalization efforts in the home state of Representative Nancy Mace, who has supported cannabis at the federal level and championed the States Reform Act, the best-looking piece of federal cannabis legislation we have seen to date.

Unfortunately, not all states have an even playing field in the U.S., and the rollout of the New York adult-use recreational market is stuttering along. The second legal door, Smacked, opened this week as a pop-up while they wait for their official location to be finalized. Located in Greenwich Village at 144 Bleecker St., Roland Conner’s Smacked is the first licensed dispensary approved through the New York Social Equity Cannabis Investment Fund. Governor Kathy Hochul noted that this marks the state’s first legal cannabis location opened by someone previously criminalized by cannabis prohibition. 

„I am so excited to become a part of history as the first individual to open a legal cannabis dispensary in New York City. Given my experience with cannabis, I never could have imagined that I would be opening a store like this,” Conner said in a statement. „But this is not just about me and my family. This is about everyone who was harmed by the draconian drug laws of the past.” 

We love seeing energy devoted to social equity in new markets and doors, and we wish all New York’s social equity license recipients the best of luck. It is unfortunate that there is so much negativity around the state’s Social Equity Fund and its complete mismanagement of the now estimated 1,400 illegal pot shops that have proliferated throughout the city. We are proponents of a thriving legal market, and it’s difficult not to see an uphill battle for operators at the state and city level. The 280e federal tax is another burden the industry bears, including the emerging social equity doors in New York. 

Do your cannabis partners a favor and buy from legal doors if you plan to purchase cannabis in New York City. There are only two shops currently open, and both are located in highly trafficked areas of lower Manhattan, making them easy to find. We cannot currently vouch for the pricing, quality or product selection, but we can’t expect the legal industry to win if we are not supporting those pushing it forward.

Research can be a powerful tool for making useful changes in our industry and society. There has been anecdotal evidence pointing to cannabis’ medicinal benefits for years, but almost as often we hear the uninformed parroting the line: „There is no research.” Well, that stigma continues to erode as we see more and more research about the societal benefits of cannabis legalization. 

According to new research (opens in new tab), states that implemented recreational cannabis laws through 2019 experienced less demand for prescription codeine. The data gathered showed a 26% decrease in the pharmacy-based distribution of codeine, and states implementing cannabis legalization before 2019 saw a distribution of codeine that was 37% lower. Codeine is known for having a high potential for abuse and causing thousands of overdose deaths per year in the U.S. Thankfully, residents in legal states have access to cannabis and therefore are seeing a notable reduction of codeine overdose deaths.

„A reduction in the misuse of opioids can save lives,” said study author Shyam Rama, a doctoral candidate at Cornell University. „Our research indicates that recreational cannabis laws substantially reduce distribution of codeine to pharmacies, an overlooked potential benefit to legalizing recreational cannabis use.”

Cannabis lobbying dollars are a drop in the bucket compared to Big Pharma. Unlike alcohol and tobacco, we are yet to see the pharmaceutical camp wanting to partner with cannabis. Instead, the cannabis industry confines its progress to Washington D.C. as pharma dollars crowd us out. There is plenty of work ahead for continued progress at the federal level.

Curaleaf Shuts Down Some Operations 

Survival and advancement by shrewd and optimal means are key themes for Poseidon (opens in new tab) in 2023. The cannabis industry is continuing its efforts to correct the challenging trajectory of 2022 as more distress comes to the surface, as seen in recent announcements from Bespoke Financial (opens in new tab) and Innovative Industrial Properties (IIPR (opens in new tab)). We’ve cautioned about debt issues in cannabis for several months, as there was too much money going under the sales pitch of debt as a „safer” way to invest in cannabis. That is generally nonsense and the results are sadly coming to fruition.

Former Intel (INTC (opens in new tab)) CEO Andy Grove once said, „Bad companies are destroyed by crisis; good companies survive them; great companies are improved by them.”

This week, we learned of significant balance sheet steps taken by the industry’s largest operator, Curaleaf (CURLF (opens in new tab)). The company is reducing its headcount by an additional 10% and shuttering operations in three states: California, Oregon and Colorado. These states were not making notable revenue contributions for Curaleaf and were operating at losses. The company claims these steps could generate $125 million in positive free cash flow in 2023, a significant shift for CURLF’s balance sheet. 

The initial reaction to the announcement was adverse, which is to be expected when we are in a bad-news environment for marijuana stocks. We disagree with the overly emotional response; these are the necessary, difficult steps that will improve companies. We knew the first company to leap would get beat up, but it would not be a surprise to see others take similar steps to rightsize their operations on their journey to generating positive free cash flow.

Cannabis M&A Market Could Struggle This Year

The evolution of mergers and acquisitions (M&A) is a long-term theme in the legal cannabis industry. M&A is also cyclical across industries, and that is no different for cannabis. There have been eventful years, followed by quiet ones and the industry coming off a much quieter 2022. We are predicting M&A to reemerge in 2023, but signs of this are more likely to appear in the second half of the year. There is little urgency to jump as most companies focus on shoring up their balance sheets, reducing cash burn or getting cash flow positive. These actions are good for solvency and survival but come at the cost of growth. 

Many companies are likely running below industry growth rates, sacrificing market share for stability. This can only go for so long before M&A comes back into consideration – there is still too much growth for the industry to forgo. We are less bullish on the distressed roll-up strategies that have recently gathered capital. 

Frank Colombo, director of analytics at Viridian Capital Advisors (opens in new tab), noted in the company’s Jan. 13 newsletter that, „One of the largest MSOs [multi-state operators] recently told us that they expected most of their M&A activity to be purchasing distressed assets.” 

As long time cannabis industry participants, we don’t see the upside in distressed assets versus working with quality businesses that are growing and attractively priced. M&A will also look favorably, especially in the earlier part of an upswing, towards good businesses at great prices over struggling businesses at lower prices.   

The Firefly 2+: A Dual-Use Vaporizer With Desktop Control And 33 … – Herb.co

Firefly offers various vaping accessories, but their flagship Firefly 2+ Weed Vaporizer is the star of the show. 

It was designed for people who love cannabis—people who love it so much they’re willing to try new ways to bring out its true, intended flavors, aromas, and effects. Firefly’s dynamic convection heating technology lets you make the most of your flower with absolutely zero waste while showing you how flavorful your herb really is. 

Designed for both dry herbs and concentrates, this state-of-the-art dual-use vaporizer is ready to hit in 3 seconds and is almost effortless to clean and load. Impressively, Firefly listened to their feedback and created the Firefly 2+ with the added feature of 33% more airflow for big, puffy, aromatic clouds. 

Plus, it’s one of the only weed vaporizers with dynamic heating from 200-500F, which you can control from your desktop or Android device. The temperature gradually increases as you draw, capping at your set maximum temperature. 

Whether you want to vape dry herbs, concentrates, or both, do it with the Firefly 2+ and experience the world of cutting-edge cannabis technology. 

For more information about Firefly, visit their website at thefirefly.com.

Manheim Family Caught Dealing Thousands Of Grams Of THC, Abusing 18 Animals, Authorities Say – Daily Voice

A Manheim family of four was caught „dealing marijuana and neglecting several animals” at their home, the Lancaster County District Attorney’s office says.

Jordan, 24; Austin, 21; Scott, 49; and Heide Breland, 46, all of the 100 block of West Colebrook Street, were arrested following a search warrant executed Jan. 13 at approximately 10:50 a.m. by Members of the Drug Task Force, with the assistance of Manheim Borough Police.

The authorities found „3,284 grams of marijuana, two digital gram scales, two boxes of sandwich bags, and used vacuum-sealed bags with marijuana residue. Additionally, 73 THC vape pens and 32 THC gummy packs were located. Thirteen total rifles and handguns with assorted ammunition and $3,488.00 were located in the residence,” the da’s office states in the release adding that, „sixteen cats and two dogs were found in the residence with several medical conditions and at least three of the cats needed medical intervention. The animals were not provided access to clean and sanitary shelter. Nine of the animals were not provided necessary veterinary care. The SPCA removed the animals from the residence.”

Austin Breland and Jordan Breland are each charged with four felonies for possession with intent to deliver marijuana and conspiracy, and for possession with intent to deliver THC and conspiracy, two misdemeanors for prohibited offensive weapon and conspiracy, and possession of drug paraphernalia, as well as 18 summary counts of neglect of an animal, and nine summary counts of neglect of an animal, failure to provide veterinary care, authorities say. 

Scott and Heide Breland are each charged with a misdemeanor count of prohibited offensive weapons and conspiracy, 18 summary counts of neglect of an animal, and nine summary counts of neglect of an animal, failure to provide veterinary care. 

They’ve all been held in the Lancaster County Prison on $100,000 bail each and their preliminary hearing has been set before Magisterial District Judge Randall L. Miller on Friday, Jan. 27, 2023 at 1:30 p.m.

to follow Daily Voice Lancaster and receive free news updates.

The Difference Between Medical and Recreational Cannabis, and Which to Choose – Lifehacker


Image for article titled The Difference Between Medical and Recreational Cannabis, and Which to Choose

Photo: SageElyse (Shutterstock)

While certainly a good way to relax, as long as humans have used it, cannabis has also been a wellness tool. From seeds discovered in ancient China to salves in ancient Egypt and spiritual smoothies in ancient India, the list is as curious as it is comprehensive, especially considering our modern outlook on the plant. Today, cannabis is either sold on the black market or hyper-regulated, and no matter why you use it, it’s harder to get than other (often much riskier) substances humans love.

As of this writing, 37 states permit medical cannabis sales, while 21 states allow adult use (also known as recreational cannabis). In those 21 latter states, both medical and recreational options are available. With this selection of purchase possibilities, which one is right for you? Why bother getting a medical card in a state where you can just hit up a recreational dispensary?

It depends on how you use cannabis, but consider this: even if you reach for an edible to help you sleep or a topical for post-workout soreness, you’re using the plant for a presumed medical purpose. Just because you can freely buy the products to serve those needs doesn’t negate that fact. If you’re soothing something that ails you, whether mental or physical, consider reframing your ‘indulgence’ as a medical or wellness aid.

Advertisement

When to consider a medical cannabis card

Obtaining a medical cannabis card can be beneficial for a few reasons, the first of which is access—many states without adult use permit medical cards for a long list of less-serious conditions.

Another less obvious perk: sticking it to the man (sort of). Government-funded cannabis research is limited, making it difficult for the plant to be fully accepted in the mainstream. If you want to know precisely why it helps you sleep soundly, participating in the patient care program helps give states (and eventually the feds) a better picture of actual use. Having a true count, one that stands in contrast with years of discreet use, could help influence cannabis policy, too.

Advertisement

One less visible benefit: medical cannabis cards and programs can help older uses who grew up alongside severe stigma against the drug consider weed a legitimate treatment for their issues.

The benefits of medical cannabis

While getting a medical card involves additional steps versus purchasing in a recreational shop, there are inherent benefits to going the medical route, including increased access in states where you don’t live. Some states, like Hawaii, provide what’s called reciprocity, where your medical card from state X is fair game in state Y—a boon for people who need the consistent and reliable access that medical outlets can provide.

Advertisement

Other states don’t have separate shops for separate types of buyers anymore, including California, which reformed its program in 2016 after decades of medical reign. But medical buyers are still treated differently, at least at the checkout: Today in California, retail adult use shops serve medical patients with the same products as recreational buyers, but certain city and state taxes are waived. These costs can be significant, and for regular medical users, the savings are worth the fees and extra steps.

In New Jersey, card holders can skip the line at the dispensary and select from a guaranteed stock and use a dedicated checkout, while adult use folks have to wait—and pray the products they want don’t sell out. Similar rules exist around possession in states like Oregon, where medical card holders can have more, or have permission to grow their own.

Advertisement

Establishing yourself as a registered patient right now could help you down the road if healthcare programs begin to consider cannabis as a legitimate treatment—perhaps one day it will be eligible for discounts, coverage, or even flexible spending accounts.

How to get a medical cannabis card

With a legitimate medical need—with the definition of “legitimate” varying from state to state—it’s generally not hard to get the documentation sorted to obtain a medical use card. Many states require only a doctor’s note, rather than a state- or county-issued physical card. Laws and regulations certainly differ from state to state; while New York might check in with you via email if you are missing paperwork, some counties in California will consider any missing detail an automatic denial unless you have a sympathetic intake staffer.

That’s where online medical use card services come in—they can get you what you need to get a card, provided you qualify and the doctor they set you up with agrees that cannabis would be a good treatment option. Sites like NuggMD, VeriHeal, and others can connect you with doctors who have experience with cannabis patients if your own doctor doesn’t feel comfortable prescribing it.

Advertisement

But when working with a site like one of the above, it’s important to remember that the company generally can’t communicate with the state on your behalf, so you typically have to be the one to forward the recommendation, your ID, proof of residency and any other needed information to your state or county agency to get final approval and obtain your physical card.

When to use recreational cannabis instead of getting a medical card

Is getting a medical card worth it if you only use occasionally, say when you’re suffering a sleepless night? It’s really your call. If you’re happy, keep doing what you’re doing. But if your use needs increase use for any medical reasons, like pain, sleep, or anxiety, consider signing up. If you have an eligible condition and just want the option, or perhaps hope to be able to shop in other states, get the process started.

Advertisement

An important additional note: If you buy cannabis for another person who uses it medically, you can get a caretaker card to help serve their needs better, so they don’t have to go to the store at all. It’s up to you how you want to shop, but the options are progressing in many states, and hopefully one day federal law will follow along.

FDA declines to regulate CBD products – Axios

Illustration of a marijuana leaf on a scale

Illustration: Sarah Grillo/Axios

The Food and Drug Administration says its current rules for regulating drugs and supplements don’t work for determining the safety of CBD products and is calling on Congress to help with a new approach.

What they’re saying: „Given the available evidence, it is not apparent how CBD products could meet safety standards for dietary supplements or food additives,” FDA principal deputy commissioner Janet Woodcock said in the statement.

Why it matters: Walk into many retailers and it’s not hard to find products — everything from oils, body lotions, lip balms, soaps, nail polish, makeup and bath bombs to candies, sparkling water and beer — containing CBD.

The big picture: The global cannabidiol market size is expected to top $22 billion by 2030, up from about $5.2 billion in 2021, according to Grand View Research.

  • Yes, but: „Studies have shown the potential for harm to the liver, interactions with certain medications and possible harm to the male reproductive system,” Woodcock’s statement read.

The other side: „The FDA continues to rely on pharmaceutical studies that show risk at significantly larger doses that are not commonly found in CBD products sold at retail,” U.S. Hemp Roundtable president Jonathan Miller said in a statement.

What to watch: The House Committee on Oversight and Accountability plans to investigate the decision, officials confirmed. The FDA did not respond to requests for comment.

FDA Announces Need for New Regulatory Pathway for CBD – Psychiatric Times

anankkml_AdobeStock

The US Food and Drug Administration (FDA) announced that a new regulatory pathway for cannabidiol (CBD) products is needed.

According to the statement—attributed to Janet Woodcock, MD, principal deputy commissioner for the FDA—careful review by an internal FDA working group concluded that the public’s desire for access to CBD products needs to be balanced with the regulatory oversight to help manage and prevent risks associated with use of CBD products.1

To this end, FDA is also denying 3 citizen petitions to allow CBD products to be marketed as dietary supplements. These findings are based on scientific literature, public information, and studies commissioned and conducted by the FDA, which identified various risks to both individuals and animals associated with the use of CBD and other cannabis-derived products.1

“The use of CBD raises various safety concerns, especially with long-term use,” Woodcock said in the statement. “Studies have shown the potential for harm to the liver, interactions with certain medications and possible harm to the male reproductive system. CBD exposure is also concerning when it comes to certain vulnerable populations such as children and those who are pregnant. A new regulatory pathway would benefit consumers by providing safeguards and oversight to manage and minimize risks related to CBD products.”

Woodcock, who also serves as chair of the working group, stated that the FDA is prepared to work with Congress in the development of a regulatory pathway for CBD products that helps minimize risks and protect the public.1 “The FDA will continue to take action against CBD and other cannabis-derived products to protect the public, in coordination with state regulatory partners, when appropriate,” Woodcock said in the statement. “We will remain diligent in monitoring the marketplace, identifying products that pose risks, and acting within our authorities.”

The issue is especially important for patients with psychiatric disorders. Although it has been suggested that cannabis may be helpful for anxiety, sleep, and depression, evidence remains limited, especially in terms of use in this patient population.2 John J. Miller, MD, Psychiatric TimesTM Editor in Chief, shared additional concerns and considerations during the most recent Annual Psychiatric TimesTM World CME Conference.3

Read the FDA’s full statement here.

References

1. FDA concludes that existing regulatory frameworks for foods and supplements are not appropriate for cannabidiol, will work with Congress on a new way forward. US Food and Drug Administration. News release. January 26, 2023. Accessed January 26, 2023. https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol?utm_medium=email&utm_source=govdelivery

2. Osser DN. Cannabis: patients with bipolar should avoid use. Psychiatric Times. 37(4):25.

3. Miller JJ. Cannabis: separating the conversation on CBD and THC. Psychiatric Times. August 22, 2022.Accessed January 26, 2023. www.psychiatrictimes.com/view/cannabis-separating-the-conversation-on-cbd-and-thc